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Differentiation of Active and Passive Response to 
Poliomyelitis Vaccine 
By 
Gordon C. Brown* 
Although I intend to make this presentation as brief as possible, I 
would like to have the opportunity to comment on a point made by  
Dr. Evans with reference to the possible necessity for developing new 
vaccines against the enteroviruses. I agree with him almost 100 per cent 
when he mentions tha t  many  of the enteroviruses other than  poliomyelitis 
cause only a relatively mild form of disease. However, I would like to 
point out tha t  in the last large epidemic of poliomyelitis which occurred 
in Michigan in 1958, we made both virological and serological studies 
on over 1,000 patients with particular reference to those patients who 
had received a full course of inactivated poliomyelitis vaccine. Many of 
the clinical illnesses which were diagnosed as poliomyelitis were para- 
lytic and some of them were fatal. Laboratory studies, however, showed 
that  some of these serious illnesses including deaths were actually caused 
by  Coxsackie type B5 and by  ECHO 9 viruses. Although this information 
is not new, I think it is well to keep in mind that  some of these other 
enteroviruses can cause quite serious clinical illness. An additional funda- 
mental  serious consequence of infection with Coxsackie virus results 
when pregnant  women or their newborn babies are infected with type B 
viruses, especially ]ate in pregnancy. These agents are frequently the cause 
of neonatal death in the young infant and in spite of this serious conse- 
quence the mother  usually shows only very mild symptoms such as a 
slight upper respiratory infection with elevation of temperature.  In  fact, 
we recently had two such cases in less than one month. I t  therefore seems 
to me tha t  one of the next  targets for immunization, in an effort to save 
the lives of young children, is to immunize pregnant women or women 
of childbearing age against the Coxsackie B viruses. I am sorry for this 
digression but  felt tha t  these points were sufficiently important  to com- 
ment  on. 
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My immediate concern has to do with one of the fundamental  points 
mentioned by Dr. David Evans, tha t  of the necessity for assuring ourselves 
of an adequate response to a vaccine if we are going to use it. Our interest 
has been with the killed rather  than the live vaccine particularly because 
we ~re interested in combinations of killed virus and bacterial vaccines. 
Such combinations, of course, would be very difficult, if not impossible, 
to perfect if one used live agents because of the phenomenon of inter- 
ference between organisms. We have done extensive studies with in- 
activated quadruple vaccines containing the antigens of diphtheria, per- 
tussis, tetanus, and the three types of poliomyelitis and at the present 
t ime are investigating a combination of killed measles and polio vaccines. 
However, we are still concerned with the problem of determining the best 
t ime to give the vaccine and with the best immunization schedule in order 
to assure the most likely satisfactory response in the young infant. Such 
a satisfactory response is complicated by the fact that  high titers of 
maternal  antibody can suppress it in a large number  of infants. Dr. Per- 
l~ins here in the audience has studied this extensively in England as has 
Dr. Wilson in Canada and several others in our country have ~lso dis- 
covered this phenomenon. The problem is even more pertinent in the 
United States where we have a situation which is apparently different 
from most of the world, namely, almost universal vaccination of pregnant 
women against poliomyelitis. I f  such women have been immunized within 
the past  two or three years, they arc still given one dose of vaccine by the 
obstetrician. I f  they have not had any previous poliomyelitis vaccine, 
they are given as many  as three doses during pregnancy. This procedure 
is fine as far as the protection of the pregnant women is concerned but 
it also results in extremely high titers of poliomyelitis antibody at the 
time of delivery with the result that  these antibodies are passively trans- 
ferred to the infant in whom it is still detectable for several months. During 
this t ime if the passive antibody titer is 1 : 16 or greater, ~n active response 
to killed vaccine will be suppressed in a large number  of children. Unless 
a pediatrician chooses to delay poliomyelitis immunization until the fifth 
or sixth month of life, and many  do not, there is no guarantee of a satis- 
factory response. We ha.re found, however, tha t  when the pr imary series 
is given at an interval of two months instead of at an interval of one 
month, the response is better. This then leads to the problem to be dis- 
cussed today;  namely, is there any way of determining which infants 
have maternally transferred passive antibody and which ones have 
actively acquired s~ntibody ? A child or young in~ant may  have neutral- 
izing antibodies which are clearly detectable by  conventional techniques 
but this does not differentiate whether they were actively or passively 
acquired. A possible means of differentiating these two types of antibody 
through fluorescent microscopy is herein presented. 
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and 87 per cent detection of fluorescent antibodies. A passive response, 
on the other hand, although 100 per cent detectable by the neutralization 
technique, results in only 37 per cent detection by the FA technique. 
Thus, in approximately two-thirds of the individuals, passive antibodies 
can be differentiated from active antibodies when this technique is 
employed. The exact explanation for this phenomenon is not clear to us 
Table 5. D i f f e r e n t i a t i o n  of A c t i v e  and P as s iv e  Response  
Provaccine  
Ant ibody  
Ti ter  
Type  of 
Response 
Ant ibody  Detec ted  
Neut .  F . A .  
Pos tvacc .  Prevacc .  Pos tvace .  Prevacc .  
None active ~ 2s/29(96%) ~ ~ ) 25/29(86%) 
Low active 1~ 1~ 2/lo(20%) 9/10(90%) 
1~ 3s/39(97%) 9/~9(21%) 34/39(87%) 
High passive 3s/3s( 100 ~ ) 39/as(100~ 14/3s(37%) ~4/3s(37%) 
at the present time, but  investigation under progress in our laboratory 
is highly suggestive that  the phenomenon is correlated with protein 
"decay"  of the passive antibody which is undergoing degradation in 
the body of the young infant and therefore this antibody does not react 
with the final labeled antiserum which has been prepared against intact 
human gamma globulin. The possible significance of a laboratory tech- 
nique to differentiate passive from actively acquired antibodies is great 
and may have far reaching consequences in the study of the response 
of young infants to active immunization procedures. 
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